These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19900255)

  • 1. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study.
    Alonso J; Croudace T; Brown J; Gasquet I; Knapp MR; Suárez D; Novick D
    Value Health; 2009 Jun; 12(4):536-43. PubMed ID: 19900255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
    Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D;
    Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia.
    Usall J; Suarez D; Haro JM;
    Psychiatry Res; 2007 Dec; 153(3):225-31. PubMed ID: 17681611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients.
    Karagianis J; Novick D; Pecenak J; Haro JM; Dossenbach M; Treuer T; Montgomery W; Walton R; Lowry AJ
    Int J Clin Pract; 2009 Nov; 63(11):1578-88. PubMed ID: 19780867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain.
    Ciudad A; Haro JM; Alonso J; Bousoño M; Suárez D; Novick D; Gilaberte I
    Eur Psychiatry; 2008 Jan; 23(1):1-7. PubMed ID: 18023154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Functional status and quality of life in Latin American outpatients with schizophrenia treated with atypical or typical antipsychotics: outcomes of the 12 months schizophrenia outpatient health outcomes (IC-SOHO) Study].
    Rovner J; Assunção S; Gargoloff P; Ibarra HS; Gasca JA; Fournais EL; Adan P; Andrades NJ; Dyachkova Y
    Vertex; 2005; 16(63):332-41. PubMed ID: 16220148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].
    Mayoral F; Montejo AL; Bousoño M; González-Torres MA; Olivares JM; Ros S; Sanjuán J; Escobar R; Lara N
    Actas Esp Psiquiatr; 2006; 34(1):7-15. PubMed ID: 16525900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study.
    Novick D; Haro JM; Suarez D; Vieta E; Naber D
    Schizophr Res; 2009 Mar; 108(1-3):223-30. PubMed ID: 19070991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Haro JM; Edgell ET; Novick D; Alonso J; Kennedy L; Jones PB; Ratcliffe M; Breier A;
    Acta Psychiatr Scand; 2005 Mar; 111(3):220-31. PubMed ID: 15701107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers.
    Ritsner MS; Gibel A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1442-52. PubMed ID: 16842897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.
    Haro JM; Suarez D; Novick D; Brown J; Usall J; Naber D;
    Eur Neuropsychopharmacol; 2007 Mar; 17(4):235-44. PubMed ID: 17137759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The European Schizophrenia Outpatient Health Outcomes Study: observational study over 36 months of the French cohort of schizophrenic outpatients treated with antipsychotics].
    Gasquet I; Chartier F; Tcherny-Lessenot S; Lépine JP
    Rev Epidemiol Sante Publique; 2009 Feb; 57(1):25-32. PubMed ID: 19162420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Gasquet I; Haro JM; Novick D; Edgell ET; Kennedy L; Lepine JP;
    Int Clin Psychopharmacol; 2005 Jul; 20(4):199-205. PubMed ID: 15933480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.
    Haro JM; Novick D; Suarez D; Alonso J; Lépine JP; Ratcliffe M;
    J Clin Psychopharmacol; 2006 Dec; 26(6):571-8. PubMed ID: 17110813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.
    Zhao Z
    Curr Med Res Opin; 2004 Jul; 20(7):1039-48. PubMed ID: 15265249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
    Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
    Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.